In December 2003, the World Economic Forum announced the designation of Procognia as one of 30 technology pioneers for 2004
Procognia has been recognised as developing and applying innovative and transformational technologies in the field of biotechnology.
The cutting-edge work of technology pioneers in fields such as biotechnology, nanotechnology and renewable energy represents an enormous resource of entrepreneurial talent.
This dynamic group is at the forefront of change in a variety of technology sectors.
In line with the forum's commitment to improving the state of the world, the technology pioneers programme was established in 2000 to provide a new perspective on technological change.
The programme identifies and integrates those companies around the world that are involved in the design and development of new technologies.
Each innovation, whether it has large or small consequences, is another step in society's attempt to harness, adapt and utilise technology to change and improve the way business and society operates.
The World Economic Forum is invested in monitoring and highlighting these innovations and exploring possible societal repercussions.
Each year members, constituents and collaborators of the World Economic Forum nominate technology pioneers.
The criteria for selection include innovation, potential impact on business and society in the future, growth and future sustainability, proof of technology concept and applications, leadership and status.
Nominees are evaluated by an external review committee comprised of technology experts.
Procognia's mission is to acquire, develop and commercialize proprietary proteomics technologies that uniquely expedite the discovery, development and manufacture of higher quality therapeutics.
Procognia's U-c fingerprint product provides a means of accurately analysing the carbohydrates on biologic products.
Carbohydrates have an important influence on the safety, efficacy and identity of biologics, but they are very difficult to analyze and control by conventional methods.
U-c fingerprint will significantly increase the speed of development and the probability of success of biologics.
Procognia's 2-c protein function array technology provides many proteins in a parallel format to increase the breadth of drug discovery and the options for screening therapeutics in development.
Other protein analysis methods used today fail to perform on the same scale or with equivalent speed.
Ron Long, CEO and chairman of Procognia said: "We are pleased to be recognised by the World Economic Forum as an innovative company in the biotechnology arena.
"Our selection is important as it supports Procognia's belief that improved proteomics tools will increase the speed and quality of medical care for patients worldwide.
"Such tools will certainly advance the field of personalised medicine".
The uniqueness of the technology pioneer network ensures that companies involved in the development of new technologies are engaged in an integrated and interdisciplinary way.
The technology pioneers community will provide the Foundation and its members with in-depth knowledge of some of the key technology issues facing society.
